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Open label extension studies: research or marketing?
G J Taylor, P Wainwright
Open label extension studies allow continued prescribing of unlicensed drugs after a randomised
trial, but it is unclear whether patients or drug companies are benefiting the most
Properly designed and conducted open label exten-
sion studies can provide rigorous information on long
term safety and tolerability of potential new drugs. This
in turn can benefit the licensing application for the
drug by providing longer term data that would
otherwise not be available until after the licence was
approved. Nevertheless, the conduct of such studies
raises several ethical and scientific concerns.1 2 As with
any research method, there are good and bad
examples. However, open label extension studies seem
particularly prone to the pressures of marketing over
good research methods and research ethics. We revisit
some of these issues and argue that we need to change
our approach to the ethical review of such studies.
Open label extension studies
Open label extension studies typically follow a double
blind randomised placebo controlled trial of a new
drug. At the end of the double blind phase, participants
are invited to enrol in an extension study. The study
will normally be longer than the randomised trial (two
years is not uncommon but they often continue until
the drug is licensed). All participants in the extension
study are given the study drug, and both they and the
investigators know this. The objective is primarily to
gather information about safety and tolerability of the
new drug in long term, day to day use.
Use of open label studies after phase III trials is
relatively common. In 2004, the multicentre research
ethics committee for Wales reviewed three open label
extension studies compared with 19 phase III studies
of new drugs, a ratio of just over 6:1. However, a recent
Medline search for studies between 2000 and 2004,
produced only 86 open label studies but over 2000
phase III studies, a ratio of 23:1. This suggests that
many open label studies are never published.
Issues of consent
The way that open label extension studies recruit raises
several questions about informed consent. Participants
are invited to join the extension study as soon as their
involvement in the randomised controlled phase III
study is finished. They do not know whether they have
been taking active or placebo treatment, and investiga-
tors will not normally unblind the study at this point.
Participants will thus base their decision on their previ-
ous study experience. Given that participants in either
arm of the trial may have had positive or negative out-
comes, their experience during the trial and their per-
ception of the efficacy of the treatment they have
received cannot be a sound basis on which to make
such a judgment. In addition, as the results of the phase
III study are unavailable, participants will be receiving a
drug without the evidence that the treatment is any
better than the standard treatment; it may potentially
be worse.
The clinical picture of some participants may also
have changed during the phase III trial. Participants
may no longer meet the inclusion criteria or may no
longer require treatment. At the conclusion of a trial
participants are normally reviewed by their doctor.
Enrolment in an extension study could result inParticipants in open label extension studies need more information
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participants taking a drug that was not clinically
justified (and often for a long time).
Another problem is that participants in the phase
III trial are often told of the possibility of the extension
study at the time of recruitment. This raises a separate
ethical concern about the validity of consent to the
phase III trial. If patients who think their present treat-
ment options are unsatisfactory are told that enrolment
in a short randomised controlled trial will ensure the
possibility of open label treatment with a new drug in
the near future, this may induce them to consent to the
initial study and might amount to coercion.
Further pressure may come from researchers
trying to get a high recruitment rate. Researchers con-
ducting an open label extension study can only recruit
from the participants in the phase III study. They may
therefore feel under pressure to recruit to ensure the
scientific merit of the study and continued income
from the funder. This may in turn encourage investiga-
tors to place pressure on participants to take part.
Unless all of these possibilities are made clear to a
potential participant during recruitment and the
researcher is not under undue pressure, the validity of
the participants’ consent is in question.
Scientific merit
The validity of data from open label extension studies
raises further questions. Open label extension studies
are commonly used to assess long term tolerability of a
new drug. However, a proportion of the participants
eligible for the study will have already taken the study
drug. Those who are unable to tolerate it are therefore
unlikely to take part in the extension study. The
absence of this group of potential participants will
introduce bias and increase the apparent tolerability of
the new drug. Analysis strategies need to be developed
and implemented to provide unbiased estimates of
safety and tolerability.
All clinical research should have clear objectives
and a clearly defined duration to which participants
may consent. However, it is not uncommon to find
protocols of open label extension studies that specify
the duration of the study as “until licence approved.”
For some participants this could mean only a few
weeks while for others it could be years, assuming the
drug is ever licensed. Such studies seem to be designed
only to promote the use of the study drug and serve no
valid research purpose.
Dressing up marketing exercises as research lends
them a spurious authority. It allows participants and
clinicians to believe they are contributing something
worthwhile to science rather than simply boosting
market share for the relevant pharmaceutical com-
pany. As the guidelines of the Council for International
Organisations of Medical Science state, “The ethical
justification of biomedical research involving human
subjects is the prospect of discovering new ways of
benefiting people’s health.”3 As marketing exercises
clearly do not hold out any such prospect, they cannot
count as ethical research activities. A key element of the
ethical review of research is the appraisal of scientific
merit, so the research ethics committee is placed in an
invidious position by applicants seeking approval for
such studies.
Compassionate use
When a promising new drug is being tested for a seri-
ous problem, doctors and patients naturally want the
drug to be available outside the period of the
randomised controlled trial. Delay is inevitable
between the completion of the trial and the granting of
a product licence, and participants who do well on the
study drug will want to continue to take it. Research
ethics committees often feel obliged to approve exten-
sion studies as the only practicable way to provide con-
tinued beneficial treatment. However, prescribing a
drug on compassionate grounds is not research, and
research ethics are therefore not a valid structure
through which to provide a treatment, however benefi-
cial. Members of research ethics committees will have
had training and experience in assessing the ethical
acceptability of a research protocol, but they will not
necessarily have the expertise to make ethical
judgments about clinical decisions involving the long
term use of novel treatments. This may be the role of
the institutional review board in some countries, but it
is not the role of the UK research ethics committee sys-
tem. Apart from their lack of relevant expertise, the
research ethics committee is an independent body with
no authority over clinical practice and no responsibility
for decisions about practice.
At the end of a participant’s involvement in a phase
III study a decision will need to be made about their
continuing treatment. The new drug may have been of
appreciable benefit to the patient, and a mechanism is
needed for the patient to receive the drug even if it is
not yet licensed, especially if there are few other treat-
ment options. However, this is not the role of an open
label extension study, and research should not be used
to mask the limitations of current regulations and pro-
cedures in drug development. Research ethics commit-
tees should not be expected to connive in such
practices, no matter how laudable the intention.
Prescribing for compassionate use is possible on a
named patient basis, and much has been published on
the prescription of unlicensed and “off label” drugs. If
researchers and clinicians believe there are grounds for
Summary points
Open label extension studies are a common
adjunct to double blind randomised controlled
trials of new drugs
The aim of open label extension studies often
seems to be to enable continued use of a new
drug for marketing or compassionate purposes
rather than to increase knowledge
The continued use of a new drug on
compassionate grounds should not be considered
within the research framework
Patients should have full information available
before deciding whether to participate
Tighter criteria need to be applied to the ethical
approval of extension studies
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the compassionate use of an as yet unlicensed product,
drug manufactures should be prepared to supply the
drug to the doctors of patients who have been shown
to benefit. The costs would, arguably, be no greater
than those for an open label study. Safety data would
still be available from these patients through the usual
monitoring systems.
Future action
Some of our concerns may also apply to other trial
designs, but our focus here is on the particular
problems of open label extension studies. Several of
the problems could be resolved by unblinding the allo-
cation of participants as they complete the phase III
study. Investigators object to this on the grounds that it
may introduce bias, but participants could be informed
of their status in the double blind trial by someone not
involved in the analysis of the trial. It has been argued
that unblinding should occur even if no open label
study follows because the subsequent treatment of par-
ticipants may be harmed if decisions are made about
further management in ignorance of their response to
the new drug.4
Open label extension studies are currently being
misused for marketing purposes or to enable compas-
sionate use of new drug. We recommend that
recruitment and consent are dealt with more openly if
the study follows a double blind trial and that potential
participants are told which arm of the trial they were in
before deciding whether to enrol. Research ethics
committees should approve studies only if they address
a genuine research question and have a clear rationale,
end points, justification of sample size, time scale, and
so on. If there is an argument for compassionate use,
committees should advise use of mechanisms such as
named patient prescriptions rather than open label
extension studies.
We thank Susan Pope for providing information from the
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our opinions.
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The rules
“Dear Editor, I read with interest your reworking of my
manuscript. Firstly here are a few things that you did
well: you checked the spelling thoroughly and you did
improve the grammar. Here’s what you could have
done better: it would have been better if you hadn’t
completely changed the tone and style and meaning of
my sentences. Yours etc.”
Pendleton’s rules are rules that help trainers give
balanced feedback to trainees.1 The idea is that, when
giving feedback, learners and teachers should
concentrate on the positive first and then say what they
thought could have been done better. If you’ve done
an advanced cardiac life support course in Britain then
you’ll be familiar with the rules. In the past many
trainers were thought to be too destructive in their
criticisms, and Pendleton’s rules are an attempt to
correct this.
But the rules do have their critics. Many say that they
add an Alice in Wonderland air to training. I’ve had a few
complaints as an editor and as a clinician, but none of
them ever read like the above letter. So why do we
encourage doctors to give and receive feedback in a
way that they will never experience in real life? It can
also be difficult to think of positive things to say to
trainees who are still in the low foothills of the learning
curve or who, worse still, have turned up to courses
without having done any preparatory work. How do
you then “accentuate the positive”? Do you say, “Well,
at least you turned up”? Perhaps the most annoying
thing about the rules is the insistence of some training
providers that you must follow them—regardless of the
learning style of the learners or the teaching style of
the teacher.
Is there an alternative? Silverman et al have
described a new way of giving feedback—called
agenda-led, outcomes based analysis.2 In this method
you start with the learners’ agenda and ask them what
problems they experienced and what help they would
like. Then you look at the outcomes that they are
trying to achieve. Next you encourage them to solve
the problems and then get the trainer and eventually
the whole group involved. Feedback should be
descriptive rather than judgmental and should also be
balanced and objective.
If you are involved in teaching and learning then
you may be interested in finding out more about these
concepts. At BMJ Learning we are building up a
resource of modules on learning and teaching. You
can find out how to run a course, give a lecture, or
even give feedback. You can give your views also. If you
disagree with Pendleton’s rules or with Silverman’s
ones or would even prefer a return to a 19th century
“gloves off” approach to feedback then we are
delighted to hear your views and to encourage debate.
Kieran Walsh clinical editor, BMJ Learning
(bmjlearning@bmjgroup.com)
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